Input parameters of the model were derived from literature, national data sources (e.g. costing data, incidence and hospitalization data) and expert opinions.
For tofacitinib, since there was access to patient-level data, incidence rates were obtained from pooling individual trials.
The total PSA (tPSA), demographic data, incidence of PCa, benign prostate hyperplasia (BPH), and prostatitis were assessed.
Consistent with published data, incidence of severe ROP was higher in Caucasians than African American infants [ 24, 25].
It demonstrated the importance of using the most updated data (incidence and survival) in the estimation process.
Our goal was to compare the standardized weighted mean difference with two alternative statistical approaches to pooling rate data, incidence rate differences and incidence rate ratios.
In agreement with previously published epidemiological data, incidence of GDM remained higher than T2DM, and pattern of incidence was comparable to that seen in other studies 8– 10.
Exposure data and disease data (incidence, prevalence or mortality data) are the most common input data sets needed for eBoD calculations.
These proportional reductions were then applied to European incidence data reflecting incidences prior to HPV vaccination implementation.
For years with missing months of incidence data, malaria incidence in the recorded months was compared with incidence in the same months in the reference year (April 2003 March 2004).
